Portfolio

Targeted Genetics

Molecular medicines for disease detection and prevention (Formerly Genevo)
(1994)

Vetgen, Inc.

Research and genetic disease detection services for all purebred animals
(1994)

GlycoGen

Developing immunomodulatory & anti-inflammatory therapeutics based on cell adhesion technology
(1992)

SoloHill Engineering, Inc.

Microcarriers and protocols for cell culture applications
(1992)

MC3

MC3 Cardiopulmonary, located in Dexter, was founded in 1991 by Robert Bartlett, M.D., a pioneering University of Michigan surgeon, and Scott Merz, PhD, to develop Extracorporeal Membrane Oxygenation (ECMO) technology for patients who would otherwise succumb to heart and lung disease.
(1991)

Aastrom

Developing autologous stem cell products for use in regenerative medicine
(1989)

BioQuant

Discovering and developing drugs for oncology, inflammation, immunology, & metabolic diseases
(1987)

TSRL, Inc.

Developing drug delivery solutions
(1987)

Arbor Ultrasound Technologies

Several ultrasound technologies for nephrologists

Cartox

In vitro cardiotoxicity testing platform using mature human stem cell derived cardiomyocytes

ExoDynamics

Smart, active spinal orthoses that provides support and mobility to users

Health IT, LLC

Behavioral Healthcare company

MEKanistic Therapeutics

MEKanistic is innovating cancer therapies by advancing a novel class of selective kinase inhibitors rationally designed to target both EGFR and PI3K with a single molecule. This breakthrough design expands the therapeutic window while avoiding inherent toxicity challenges of multi-compound treatments. Preclinical studies of its lead drug MTX-531 show a high incidence of tumor regression with dramatically reduced toxicity.

STEL Technologies

Developing a bioengineered construct for ACL repair